دورية أكاديمية
Roxadustat-Induced Central Hypothyroidism in Renal Anemia Patients: Insights From Antineutrophil Cytoplasmic Antibody-Related Vasculitis Cases.
| العنوان: | Roxadustat-Induced Central Hypothyroidism in Renal Anemia Patients: Insights From Antineutrophil Cytoplasmic Antibody-Related Vasculitis Cases. |
|---|---|
| المؤلفون: | Omote D; Nephrology, Narita Red Cross Hospital, Narita-shi, JPN., Kuramoto N; Nephrology, Narita Red Cross Hospital, Narita-shi, JPN., Tomikawa A; Rheumatology, Narita Red Cross Hospital, Narita-shi, JPN., Yasui M; Rheumatology, Narita Red Cross Hospital, Narita-shi, JPN., Fukuta M; Rheumatology, Narita Red Cross Hospital, Narita-shi, JPN., Hiraguri M; Rheumatology, Narita Red Cross Hospital, Narita-shi, JPN. |
| المصدر: | Cureus [Cureus] 2024 Jun 06; Vol. 16 (6), pp. e61843. Date of Electronic Publication: 2024 Jun 06 (Print Publication: 2024). |
| نوع المنشور: | Case Reports; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Cureus, Inc Country of Publication: United States NLM ID: 101596737 Publication Model: eCollection Cited Medium: Print ISSN: 2168-8184 (Print) Linking ISSN: 21688184 NLM ISO Abbreviation: Cureus Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Palo Alto, CA : Cureus, Inc. |
| مستخلص: | The introduction of hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors in Japan in 2019 for treating renal anemia in hemodialysis patients has resulted in an adverse event: central hypothyroidism. Although this adverse event was not widely recognized by the public, it was first documented in Japan in 2021. Despite limited case reports on roxadustat, an oral HIF-PH inhibitor that induces central hypothyroidism, this condition typically improves rapidly upon discontinuation of the drug. In this report, we present rare cases of roxadustat-induced central hypothyroidism in two patients: a woman in her 80s and a man in his 60s, neither of whom had prior thyroid disease. Both patients developed central hypothyroidism shortly after starting roxadustat treatment for renal anemia associated with antineutrophil cytoplasmic antibody-related vasculitis. Notably, neither patient had pituitary tumors or other pituitary hormone disorders. Thyroid function improved with levothyroxine treatment, even when oral roxadustat was continued. Roxadustat may induce central hypothyroidism, highlighting the importance of regularly measuring and evaluating thyroid function when administering this drug to monitor possible changes in thyroid hormone levels. Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. (Copyright © 2024, Omote et al.) |
| References: | Proc Natl Acad Sci U S A. 2016 May 3;113(18):E2516-25. (PMID: 27091985) iScience. 2019 Oct 25;20:489-496. (PMID: 31655060) BMC Nephrol. 2021 Mar 20;22(1):104. (PMID: 33743638) Clin Kidney J. 2021 Jan 20;14(5):1472-1474. (PMID: 33959275) |
| فهرسة مساهمة: | Keywords: anca-related vasculitis; central hypothyroidism; hif-ph inhibitors; renal anemia; roxadustat |
| تواريخ الأحداث: | Date Created: 20240708 Latest Revision: 20240709 |
| رمز التحديث: | 20240709 |
| مُعرف محوري في PubMed: | PMC11227460 |
| DOI: | 10.7759/cureus.61843 |
| PMID: | 38975517 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2168-8184 |
|---|---|
| DOI: | 10.7759/cureus.61843 |